Case study

Back to subjects     Back to universities

Use of new diagnostic medical technology to improve detection of abnormal blood clotting: the health and economic benefits

Swansea University leads the world in blood clot detection

Based on the early findings of the Complex Fluids group led by Professor P R Williams, researchers at Swansea University have developed a much improved way of detecting abnormal blood clots which can be responsible for some 25,000 preventable deaths in UK hospitals every year.

The new test provides clinicians with the earliest possible indication of altered clot structure.  The demand for improved testing is huge, as NICE guidelines require that all 1.3m people admitted to hospital each year are screened for clotting abnormalities.

The test is already being used abroad (by Pennsylvania University for example), and has led to the establishment of an EPSRC Healthcare Impact Partnership at specialist laboratories within Swansea’s NHS Morriston Hospital (led by Professor PA Evans).  The invention has also attracted substantial commercial investment:  Highly skilled jobs have been created in two companies set up to exploit the IP related to the award-winning test, and the medical device company, Haemair Ltd, has relocated to Swansea as a result.

“Swansea’s haemorheology technology has been a key underpinning and enabling technology in the development, testing, trialling and sale of our products. Our need to exploit it was a principal driver in the company’s decision to locate, recruit and operate at Swansea University and … our ability to attract ongoing investment.” Operations Manager, Haemair Ltd

Find out more